INVA Innoviva, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1080014 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.8%
TTM net income YoY51.9%
TTM EPS YoY41.6%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR57.1%
Margins
Gross margin74.5%
Operating margin38.8%
Net margin44.1%
FCF margin41.6%
EBITDA margin—
Returns
ROE18.0%
ROA13.0%
ROIC (approx.)18.3%
Asset turnover0.30x
Leverage & solvency
Liabilities / assets26.0%
Debt / equity0.23x
Current ratio15.44x
Interest coverage8.64x
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio0.7%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $106.12M | $119.59M | $97.99M | $114.61M | $107.80M | $100.28M | $88.63M | $91.81M |
| Gross profit | $84.38M | $90.62M | $75.83M | $75.67M | $75.54M | $83.15M | $73.31M | $78.13M |
| R&D expense | $5.21M | $5.19M | $5.24M | $4.55M | $13.67M | $7.98M | $4.40M | $3.67M |
| SG&A expense | $37.02M | $34.57M | $32.44M | $32.12M | $27.29M | $26.41M | $27.49M | $31.33M |
| Operating income | $42.15M | $50.85M | $38.15M | $38.99M | $34.58M | $48.75M | $41.43M | $43.14M |
| Interest expense | $5.47M | $5.47M | $5.44M | $3.31M | $4.01M | $4.66M | $4.71M | $4.75M |
| Pretax income | -$97.61M | -$108.02M | $234.56M | $195.04M | $97.82M | $72.60M | -$38.59M | $24.69M |
| Income tax | -$23.72M | -$24.60M | $47.97M | $30.88M | $7.91M | $8.91M | $8.00M | $4.36M |
| Net income | -$73.89M | -$83.42M | $186.59M | $164.15M | $89.91M | $63.69M | -$46.58M | $20.33M |
| EPS (basic) | -1.03 | -1.14 | 2.52 | — | 1.30 | 1.01 | -0.74 | — |
| EPS (diluted) | -1.03 | -1.14 | 2.22 | — | 1.08 | 0.77 | -0.74 | — |
| Weighted avg. shares (diluted) | 72.07M | 73.42M | 84.85M | — | 84.96M | 84.45M | 62.71M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $581.39M | $570.39M | $603.09M | $550.94M | $476.51M | $397.53M | $319.09M | $304.96M |
| Inventory | $42.84M | $38.97M | $38.84M | $39.17M | $38.36M | $49.00M | $41.48M | $33.73M |
| Current assets | $772.25M | $753.37M | $772.62M | $727.51M | $684.57M | $651.78M | $582.02M | $554.31M |
| PP&E, net | $2.04M | $2.13M | $2.14M | $1.55M | $1.53M | $451,000 | $483,000 | $514,000 |
| Goodwill | $17.91M | $17.91M | $17.91M | $17.91M | $17.91M | $17.91M | $17.91M | $17.91M |
| Intangibles | $162.28M | $168.98M | $175.60M | $182.16M | $188.79M | $195.41M | $201.96M | $208.43M |
| Total assets | $1.54B | $1.70B | $1.84B | $1.64B | $1.43B | $1.33B | $1.25B | $1.30B |
| Current liabilities | $50.03M | $47.06M | $36.56M | $49.70M | $48.47M | $246.56M | $234.75M | $236.08M |
| Short-term debt | — | — | — | $0 | $0 | $191.90M | $192.22M | $192.03M |
| Long-term debt | $258.82M | $258.45M | $258.10M | $257.73M | $257.38M | $257.02M | $256.67M | $256.32M |
| Total debt | $258.82M | $258.45M | $258.10M | $257.73M | $257.38M | $448.92M | $448.88M | $448.34M |
| Total liabilities | $400.41M | $469.46M | $494.93M | $462.32M | $419.15M | $618.75M | $607.49M | $609.90M |
| Shareholders' equity | $1.14B | $1.23B | $1.34B | $1.17B | $1.01B | $714.82M | $646.90M | $691.16M |
| Net debt | -$322.57M | -$311.93M | -$344.99M | -$293.21M | -$219.14M | $51.39M | $129.79M | $143.38M |
| Shares outstanding | 71.54M | 72.64M | 73.81M | 74.64M | 74.77M | 63.01M | 62.77M | 62.66M |
| Cash flow statement | ||||||||
| Operating cash flow | $41.70M | $51.97M | $35.28M | $54.51M | $49.73M | $44.07M | $48.62M | $59.24M |
| Capital expenditure | $24,000 | $429,000 | $492,000 | $10,000 | $1.12M | $0 | $0 | $0 |
| Free cash flow | $41.67M | $51.54M | $34.79M | $54.50M | $48.61M | $44.07M | $48.62M | $59.24M |
| Investing cash flow | -$5.43M | -$55.26M | $37.01M | $23.64M | $18.41M | $33.12M | -$34.67M | -$15.48M |
| Financing cash flow | -$25.26M | -$29.41M | -$20.15M | -$3.72M | $10.84M | $1.25M | $183,000 | $573,000 |
| Stock-based compensation | $3.67M | $4.74M | $2.57M | $2.50M | $2.38M | $2.42M | $2.15M | $1.67M |
| Share buybacks | $26.07M | $31.07M | $20.25M | $4.53M | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.